352,096 Biogen Inc. $BIIB Shares Acquired by USS Investment Management Ltd

Biogen logo with Healthcare background
Image from MarketBeat Media, LLC.

USS Investment Management Ltd increased its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 809.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 395,613 shares of the biotechnology company's stock after buying an additional 352,096 shares during the period. USS Investment Management Ltd owned about 0.27% of Biogen worth $89,361,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Bell Investment Advisors Inc acquired a new position in Biogen in the 2nd quarter valued at about $27,000. Align Financial LLC lifted its holdings in Biogen by 339.3% in the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 95 shares in the last quarter. Provenance Wealth Advisors LLC acquired a new stake in shares of Biogen during the 3rd quarter worth about $29,000. Canton Hathaway LLC acquired a new stake in shares of Biogen during the 3rd quarter worth about $31,000. Finally, Financial Freedom LLC purchased a new stake in shares of Biogen during the third quarter worth about $34,000. 87.93% of the stock is owned by institutional investors and hedge funds.

More Biogen News

Here's some of the latest news about BIIB:

  • Positive Sentiment: Biogen also reported encouraging two-year Phase 2 results for diranersen in early Alzheimer’s, adding to its longer-term Alzheimer’s pipeline prospects. Diranersen two-year data
  • Neutral Sentiment: The α-synuclein results came from a limited subgroup (82 patients) and a post hoc analysis, so they may be less conclusive than findings from a prospective trial. Clarity AD analysis details
  • Negative Sentiment: A recent analyst commentary downgraded Biogen, arguing that M&A-driven growth and Alzheimer’s progress may already be priced in. Another report described analyst views as mixed, potentially limiting enthusiasm despite the favorable data. Biogen rating downgrade commentary

Biogen Stock Down 1.7%

Shares of BIIB opened at $247.13 on Friday. Biogen Inc. has a fifty-two week low of $160.36 and a fifty-two week high of $261.00. The company's fifty day moving average is $236.18 and its two-hundred day moving average is $206.49. The firm has a market cap of $36.53 billion, a PE ratio of 105.61, a price-to-earnings-growth ratio of 2.85 and a beta of 0.10. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.63. The firm had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.63 billion. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.81 earnings per share. Analysts forecast that Biogen Inc. will post 12.46 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BIIB shares. Zacks Research raised shares of Biogen from a "strong sell" rating to a "hold" rating in a research report on Tuesday, July 28th. Morgan Stanley raised their target price on shares of Biogen from $231.00 to $238.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 29th. Robert W. Baird raised their target price on shares of Biogen from $250.00 to $290.00 and gave the stock an "outperform" rating in a research report on Thursday, October 29th. Argus raised Biogen from a "hold" rating to a "buy" rating and set a $280.00 price target on the stock in a research note on Thursday, October 29th. Finally, Stifel Nicolaus set a $242.00 price target on Biogen in a research note on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $254.41.

Check Out Our Latest Stock Analysis on BIIB

Biogen Company Profile

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

Read More

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Biogen Right Now?

Before you consider Biogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.

While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines